Stephen Knight

CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA.

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA.

NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY.

Iora Health, Inc. engages in the provision of healthcare services. It operates a primary care practice for college employees and their adult dependents; a clinic that serves hotel and restaurant workers; a family practice for individuals who receive health insurance; and a primary care practice to provide services to carpenters and their family members. The company was founded by Rushika Fernandopulle and Christopher J. McKown in 2010 and is headquartered in Cambridge, MA.

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA.

Veritas Medicine, Inc. operates an online database of clinical trials. It offers patient enrollment solutions to determine eligibility for upcoming clinical trials. The company was founded by Robert Adelman, Joshua Schultz, and Stephen Knight in 1999 and is headquartered in Cambridge, MA.

Bell Laboratories provides research and development services. It provides communications technologies including transistors, digital networking, signal processing, lasers and fiber-optic communications systems, communication satellites, cellular telephony, electronic switching of calls, touch-tone dialing and modems. The company was founded in 1925 and is headquartered in Murray Hill, NJ.

PathoGenetix, Inc. operates as a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. Its Genome Sequence Scanning technology isolates and analyzes DNA from an enriched biological sample, without the need for a cultured isolate. The firm specializes in food safety, industrial microbiology, and clinical diagnostics and research. The company was founded in 1997 and is headquartered in Watertown, MA.

RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom.

Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston.

F-Prime UK Ltd. was founded in 2007 and provides strategy development, market research, investment advisory, and administration support services. The private company is based in London, UK.

Bio Palette Co., Ltd. provides genetic modification services for microbes, therapeutics and agriculture industries. The company was founded by Shoko Murase and Akihiko Kondo on February 21, 2017 and is headquartered in Kobe, Japan.

Atalanta Therapeutics, Inc. develops RNA interference based therapeutics to treat neurodegenerative diseases. The company is based in Boston, MA. The company was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova, Jim Glasheen. The CEO is Alicia Secor.

Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA.

Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.

Proof Diagnostics, Inc. is a company that specializes in providing affordable and accessible COVID-19 molecular testing using CRISPR technology. The company is based in Cambridge, MA. Led by world-renowned molecular biologist Dr. Feng Zhang, the company aims to help communities take control of their health. Proof Diagnostics was founded in 2020 by Feng Zhang, Sid Shenai, Jonathan Gootenberg, Omar Abudayyeh. Sid Shenai has been the CEO since 2020.

Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya.

Paradigm Health, Inc. develops a platform for clinical research. The company is based in New York, NY and has subsidiaries in the United States. The company was founded by Milind Kamkolkar. Kent Thoelke has been the CEO of the company since 2023.

Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA.